NEW YORK, December 29, 2025, 05:02 ET — Premarket
- BillionToOne shares last rose 3.4% to $89.30 at Friday’s close; they last traded at $89.40 in after-hours trading. 1
- The diagnostics maker’s most recent update showed 117% revenue growth in Q3 and operating income of $9.6 million. 2
- Investors are watching the company’s January presentation at the J.P. Morgan Healthcare Conference and its next earnings date in late February. 3
BillionToOne, Inc shares rose 3.4% to $89.30 at Friday’s close. The stock last traded at $89.40 in after-hours activity, trading that takes place after the regular session ends, according to Investing.com. 1
The newly public molecular diagnostics company heads into the final trading week of the year with few near-term catalysts before a big healthcare investor conference in January. 3
BillionToOne’s most recent quarterly report set a high bar: the company posted sharp revenue growth and swung to operating profit, while issuing full-year revenue guidance, it said in a results release filed with the U.S. securities regulator. 2
Total revenue climbed to $83.5 million in the third quarter ended Sept. 30, up 117% from a year earlier, the company said. Prenatal clinical testing revenue was $74.1 million, while oncology clinical testing revenue rose to $8.7 million from $1.1 million a year ago. 2
BillionToOne said it accessioned 162,900 tests — meaning samples received for processing — up 51% from a year earlier. It reported an overall average selling price, or ASP, of $501, a measure of average revenue per test delivered. 2
Gross margin, a measure of profitability after direct costs, rose to 70% from 53% a year earlier, the company said. Operating income was $9.6 million, compared with an operating loss of $12.6 million in the prior-year quarter. 2
“This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics,” Chief Executive Dr. Oguzhan Atay said. 2
BillionToOne forecast full-year 2025 revenue of $293 million to $299 million and fourth-quarter revenue of $84 million to $90 million. It also said it expects positive GAAP operating income for both the fourth quarter and the full year. 2
The company said it raised gross proceeds of $314.0 million in its initial public offering, which closed on Nov. 7. BillionToOne priced its IPO at $60 a share, according to a Reuters report, putting the stock about 49% above that level at Friday’s close. 2
BillionToOne, based in Menlo Park, California, sells molecular diagnostics used in prenatal screening and oncology testing. Its core technology, Quantitative Counting Templates, is designed to count DNA molecules at the single-molecule level, the company said. 2
Investors will look for updates when management presents at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, 2026, according to a company announcement. 3
Traders are also watching the company’s next earnings date, listed as Feb. 25, 2026, on Investing.com. 1
On the chart, the stock traded between $85.62 and $89.99 in the last regular session and has ranged from $81.51 to $138.70 over the past 52 weeks, according to Investing.com data. 1
